FDA Clears Molnlycke Transfer Dressing That Offers Reduction in Trauma and Infection Risk

The Food and Drug Administration (FDA) has cleared a transfer dressing from Mölnlycke Health Care U.S., a dressing that minimizes trauma and reduces risk of infection.

Mepilex® Transfer Ag is a wound contact layer that minimizes infection while providing less-painful healing. It is the worlds first antimicrobial transfer dressing with Safetac® technology.

Mepilex Transfer Ag uses the bacterial-reducing power of silver, says Josh Way, product manager at Mölnlycke Health Care U.S. It is ideal for treating exuding and difficult to dress wounds.

Using Safetac® technology for gentle adhesion and minimal wound disturbance and pain, Mepilex Transfer Ag creates an optimal environment for the body to heal the wound.(1) Safetac technology provides an undisturbed healing environment. It adheres gently to dry tissue but not to moist wound surfaces. It also molds to the skin's irregularities, covering more skin surface and spreading peel forces on removal to prevent skin stripping.

Mepilex Transfer Ag also provides a combined rapid and sustained antimicrobial effect and has a soft, flexible foam technology that absorbs and transfers exudate away from the wound. (2) By moving exudate, the dressing minimizes the risk of maceration and enables management of difficult-to-dress wounds. It also allows for fewer dressing changes, since clinicians can leave the wound contact layer in place and replace only the secondary layer.

Source: Mölnlycke Health Care

References:

1.  White R. A multinational survey of the assessment of pain when removing dressings. Wounds UK, 2008

2. External lab report; NAMSA